Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Wanxing Bio-pharmaceuticals
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Wanxing has progressed recombinant human kallikrein to IND filing for brain infarction in China, and ran a Phase 1 trial on a recombinant malaria vaccine (PfCP2.9), demonstrating immunogenicity and safety[6][8].
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Recombinant proteinEnzymeVaccine
- Industry
- Biotech
02
Partnerships
Montanide adjuvant partner (Phase 1 malaria vaccine trial, likely SEPPIC or affiliates for Montanide ISA 720[8])
Beyond the preview
Go deeper on Shanghai Wanxing Bio-pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Wanxing Bio-pharmaceuticals.